- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Ted Okon Outlines the Importance of Payer-Provider Dialogues
The current dialogue occurring between payers and providers is critical in today's healthcare environment, and it's an interaction that certainly was not happening just 5 or 6 years ago, according to Ted Okon, executive director of the Community Oncology Alliance.
The current dialogue occurring between payers and providers is critical in today's healthcare environment, and it's an interaction that certainly was not happening just 5 or 6 years ago, according to Ted Okon, executive director of the Community Oncology Alliance (COA).
Transcript (slightly modified)
What is the importance of the dialogue between payers and providers in the current healthcare landscape?
I think the dialogue between providers and payers in the current healthcare environment is absolutely critical. We need to talk, we need to communicate. We need to basically have a dialogue about what is working in payment reform and what is not. And the thing that we heard at COA's Payer Exchange Summit and we constantly hear at the summit's we've done with providers and payers, that oncology payment reform is actually working. And what we need to do is, we need to look at what's working, what can we do better, if something is not working then what can we do differently.
So this dialogue is really critical. And the interesting thing is that 5 or 6 years ago there was no dialogue. There was actually no constructive interactions between providers and payers, certainly not like we're seeing today.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Targeting Progression: Amivantamab’s Role in NSCLC After Osimertinib
October 24th 2024Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials.
Read More
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
